Antiretroviral prescribing patterns in the Texas prison system

被引:25
作者
Baillargeon, J
Borucki, MJ
Zepeda, S
Jenson, HB
Leach, CT
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78284 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA
[3] Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77550 USA
[4] Univ Houston, Coll Pharm, Managed Hlth Care Div, Galveston, TX USA
关键词
D O I
10.1086/317478
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although the prevalence of human immunodeficiency virus (HIV) infection among prison inmates is reported to be high, little is known about anti-HIV treatment patterns in correctional institutions. The present study assessed antiretroviral prescribing patterns for 2360 Texas Department of Criminal Justice (TDCJ) inmates infected with HIV. In 1998, 66.8% of all TDCJ inmates infected with HIV who had CD4 lymphocyte counts <500 cells/mm(3) were treated with highly active antiretroviral therapy (HAART). However, no substantial differences in the use of HAART were exhibited according to the sociodemographic factors under study. While the majority of inmates receiving HAART in 1998 were prescribed a combination of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor, 11.2% were prescribed a combination of 2 NRTIs and 1 non-NRTI. In view of the elevated rate of HIV infection in correctional settings, it will be important to continue to document the pharmacotherapy patterns among prison inmates, both during and following incarceration.
引用
收藏
页码:1476 / 1481
页数:6
相关论文
共 22 条
[1]  
ANNO B, 1997, HDB HLTH BEHAV RES, P289
[2]   Compliance with antidepressant medication among prison inmates with depressive disorders [J].
Baillargeon, J ;
Contreras, S ;
Grady, JJ ;
Black, SA ;
Murray, O .
PSYCHIATRIC SERVICES, 2000, 51 (11) :1444-1446
[3]  
Baillargeon J, 2000, ANN EPIDEMIOL, V10, P74, DOI 10.1016/S1047-2797(99)00033-2
[4]   Protease inhibitors for HIV infection [J].
Bartlett, JG .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1086-1088
[5]  
BRAITHWAITE R, 1996, PRISON AIDS PUBLIC H
[6]   Clinical experience and choice of drug therapy for human immunodeficiency virus disease [J].
Brosgart, CL ;
Mitchell, TF ;
Coleman, RL ;
Dyner, T ;
Stephenson, KE ;
Abrams, DI .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :14-22
[7]  
DAQUILA R, 1997, NEW ENGL J MED, V337, P734
[8]  
Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection, 1999, GUID US ANT AG HIV I
[9]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[10]  
Gilliard D., 1999, PRISON JAIL INMATES